CA2260858C - Polynucleotide vaccine formulation against pathologies of the horse - Google Patents
Polynucleotide vaccine formulation against pathologies of the horse Download PDFInfo
- Publication number
- CA2260858C CA2260858C CA2260858A CA2260858A CA2260858C CA 2260858 C CA2260858 C CA 2260858C CA 2260858 A CA2260858 A CA 2260858A CA 2260858 A CA2260858 A CA 2260858A CA 2260858 C CA2260858 C CA 2260858C
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- plasmid
- equine
- eiv
- vivo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000283073 Equus caballus Species 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000007170 pathology Effects 0.000 title abstract description 10
- 238000009472 formulation Methods 0.000 title description 27
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title description 8
- 239000013612 plasmid Substances 0.000 claims abstract description 114
- 229960005486 vaccine Drugs 0.000 claims abstract description 94
- 238000001727 in vivo Methods 0.000 claims abstract description 29
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 27
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 27
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 27
- 230000002163 immunogen Effects 0.000 claims abstract description 19
- 230000028993 immune response Effects 0.000 claims abstract description 12
- 230000001939 inductive effect Effects 0.000 claims abstract description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 18
- 229940031626 subunit vaccine Drugs 0.000 claims description 12
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 10
- 229940124551 recombinant vaccine Drugs 0.000 claims description 10
- 230000006698 induction Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 36
- 239000000427 antigen Substances 0.000 abstract description 19
- 108091007433 antigens Proteins 0.000 abstract description 19
- 102000036639 antigens Human genes 0.000 abstract description 19
- 230000001717 pathogenic effect Effects 0.000 abstract description 9
- 244000052769 pathogen Species 0.000 abstract description 7
- 239000012634 fragment Substances 0.000 description 59
- 108091034117 Oligonucleotide Proteins 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 48
- 241000589969 Borreliella burgdorferi Species 0.000 description 40
- 241000700605 Viruses Species 0.000 description 27
- 238000003757 reverse transcription PCR Methods 0.000 description 26
- 241000230501 Equine herpesvirus sp. Species 0.000 description 23
- 201000002491 encephalomyelitis Diseases 0.000 description 22
- 239000013598 vector Substances 0.000 description 20
- 241000283086 Equidae Species 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 108090000288 Glycoproteins Proteins 0.000 description 10
- 102000003886 Glycoproteins Human genes 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 101150039660 HA gene Proteins 0.000 description 6
- 206010043376 Tetanus Diseases 0.000 description 6
- 229940031551 inactivated vaccine Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229940031348 multivalent vaccine Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101150082674 E2 gene Proteins 0.000 description 4
- 208000016604 Lyme disease Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000711798 Rabies lyssavirus Species 0.000 description 4
- 108010055044 Tetanus Toxin Proteins 0.000 description 4
- 206010003230 arteritis Diseases 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 229940031346 monovalent vaccine Drugs 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101150111062 C gene Proteins 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108700006640 OspA Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940118376 tetanus toxin Drugs 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 description 2
- 108010015149 Equid herpesvirus 4 glycoprotein D Proteins 0.000 description 2
- 101150082239 G gene Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101150118742 NP gene Proteins 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 101150029683 gB gene Proteins 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 101100380241 Caenorhabditis elegans arx-2 gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000617805 Homo sapiens Staphylococcal nuclease domain-containing protein 1 Proteins 0.000 description 1
- 101000830894 Homo sapiens Targeting protein for Xklp2 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101000942603 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Condensin complex subunit 3 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 101000963191 Xenopus laevis Maternal DNA replication licensing factor mcm3 Proteins 0.000 description 1
- 101150092805 actc1 gene Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002096 anti-tetanic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 101150036031 gD gene Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 101150045801 ospA gene Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2660355A CA2660355C (en) | 1996-07-19 | 1997-07-15 | Polynucleotide vaccine formulation against pathologies of the horse |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9609400A FR2751226B1 (fr) | 1996-07-19 | 1996-07-19 | Formule de vaccin polynucleotidique contre les pathologies du cheval |
| FR9609400 | 1996-07-19 | ||
| PCT/FR1997/001314 WO1998003198A1 (fr) | 1996-07-19 | 1997-07-15 | Formule de vaccin polynucleotidique contre les pathologies du cheval |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2660355A Division CA2660355C (en) | 1996-07-19 | 1997-07-15 | Polynucleotide vaccine formulation against pathologies of the horse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2260858A1 CA2260858A1 (en) | 1998-01-29 |
| CA2260858C true CA2260858C (en) | 2011-01-18 |
Family
ID=9494494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2260858A Expired - Lifetime CA2260858C (en) | 1996-07-19 | 1997-07-15 | Polynucleotide vaccine formulation against pathologies of the horse |
| CA2660355A Expired - Lifetime CA2660355C (en) | 1996-07-19 | 1997-07-15 | Polynucleotide vaccine formulation against pathologies of the horse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2660355A Expired - Lifetime CA2660355C (en) | 1996-07-19 | 1997-07-15 | Polynucleotide vaccine formulation against pathologies of the horse |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6207166B1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP0936922B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2000516199A (cg-RX-API-DMAC10.html) |
| AR (2) | AR009947A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU735372B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR9710502A (cg-RX-API-DMAC10.html) |
| CA (2) | CA2260858C (cg-RX-API-DMAC10.html) |
| CZ (2) | CZ300593B6 (cg-RX-API-DMAC10.html) |
| DE (1) | DE69734778T2 (cg-RX-API-DMAC10.html) |
| FR (1) | FR2751226B1 (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ333754A (cg-RX-API-DMAC10.html) |
| PL (1) | PL188409B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1998003198A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751226B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| FR2776928B1 (fr) * | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
| FR2794648B1 (fr) * | 1999-06-10 | 2003-03-07 | Merial Sas | Vaccins adn pour animaux de compagnie et de sport |
| US6645740B1 (en) | 1999-06-10 | 2003-11-11 | Merial Limited | Nucleic acids encodings equine GM-CSF |
| WO2000077043A2 (fr) * | 1999-06-10 | 2000-12-21 | Merial | Vaccins adn pour animaux de compagnie et de sport |
| AU2001252390A1 (en) * | 2000-05-01 | 2001-11-12 | Powderject Vaccines, Inc. | Nucleic acid immunization |
| US6803041B2 (en) * | 2001-03-20 | 2004-10-12 | Boehringer Ingelheim Vetmedica, Inc. | Equine herpesvirus vaccine |
| FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
| US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
| EP1606419A1 (en) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| MXPA06005424A (es) | 2003-11-13 | 2007-01-25 | Univ Georgia Res Found | Metodos para caracterizar virus de enfermedad bursal infecciosa. |
| ATE510928T1 (de) | 2004-02-19 | 2011-06-15 | Univ Alberta | Leptinpromotor-polymorphismen und verwendungen davon |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| HRP20100314T1 (hr) | 2005-04-25 | 2010-08-31 | Merial Ltd. | Cjepivo protiv nipah virusa |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| EP1951751B1 (en) | 2005-11-14 | 2017-11-01 | Merial, Inc. | Gene therapy for renal failure |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| SI2147105T1 (sl) | 2007-05-02 | 2013-08-30 | Merial Limited | DNA-plazmidi z izboljšano ekspresijo in stabilnostjo |
| US20080274137A1 (en) * | 2007-05-02 | 2008-11-06 | Jean Christophe Francis Audonnet | DNA plasmids having improved expression and stability |
| EP3168307B1 (en) | 2008-11-28 | 2020-07-15 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant avian influenza vaccine and uses thereof |
| WO2010115133A2 (en) | 2009-04-03 | 2010-10-07 | Merial Limited | Newcastle disease virus vectored avian vaccines |
| US10633667B2 (en) | 2009-12-28 | 2020-04-28 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant NDV antigen and uses thereof |
| US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
| EP3093025B1 (en) | 2010-03-12 | 2018-08-01 | Merial Inc. | Bluetongue virus recombinant vaccines and uses thereof |
| CN103269714B (zh) | 2010-08-31 | 2016-06-29 | 梅里亚有限公司 | 以新城疫病毒为载体的疱疹病毒疫苗 |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| EP2694677A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| US20140287931A1 (en) | 2011-04-04 | 2014-09-25 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| AU2012245395A1 (en) | 2011-04-20 | 2013-11-14 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| JP6407714B2 (ja) | 2011-04-25 | 2018-10-17 | アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド | 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物 |
| MX361804B (es) | 2011-05-27 | 2018-12-17 | Boehringer Ingelheim Animal Health Usa Inc | Vacunas genéticas contra el virus hendra y el virus nipah. |
| US9669085B2 (en) | 2011-06-01 | 2017-06-06 | Merial Inc. | Needle-free administration of PRRSV vaccines |
| ES2626297T3 (es) | 2011-08-12 | 2017-07-24 | Merial, Inc. | Preservación asistida por vacío de productos biológicos, en particular de vacunas |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| EP3466443B1 (en) | 2012-02-14 | 2020-12-16 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
| US9446117B2 (en) | 2012-02-14 | 2016-09-20 | Merial, Inc. | Rotavirus subunit vaccines and methods of making and use thereof |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| KR101490292B1 (ko) | 2012-04-16 | 2015-02-04 | 한국생명공학연구원 | 신규한 ｈ3ｎ8 말 인플루엔자 바이러스 |
| ES2664069T3 (es) | 2012-06-13 | 2018-04-18 | Merial, Inc. | Vacunas contra BTV y AHSV de genoma reordenado |
| US9556419B2 (en) | 2013-03-12 | 2017-01-31 | Merial Inc. | Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof |
| US10010499B2 (en) | 2014-11-03 | 2018-07-03 | Merial Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| DK3313864T3 (da) | 2015-06-23 | 2021-11-01 | Boehringer Ingelheim Animal Health Usa Inc | Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf |
| WO2017031120A1 (en) | 2015-08-20 | 2017-02-23 | Merial, Inc. | Fcv recombinant vaccines and uses thereof |
| MA43016A (fr) | 2015-09-29 | 2018-08-08 | Merial Inc | Vaccins à particules pseudo-virales (vlp) de parvovirus canin (cpv) et utilisations associées |
| RU2714428C2 (ru) | 2015-11-23 | 2020-02-14 | Мериал, Инк. | Слитые белки fmdv-e2 и их применение |
| TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
| CN109136264B (zh) * | 2018-09-19 | 2022-07-29 | 天康制药(苏州)有限公司 | 马疱疹病毒1型gB-gD融合蛋白、重组载体和真核细胞株及其制备方法和疫苗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4631191A (en) * | 1985-06-20 | 1986-12-23 | Biotechnology Research Partners, Ltd. | Methods and compositions useful in preventing equine influenza |
| US4944942A (en) * | 1987-08-27 | 1990-07-31 | Mobay Corporation | Intranasal vaccination of horses with inactivated microorganisms or antigenic material |
| SU1671688A1 (ru) * | 1989-01-27 | 1991-08-23 | Всесоюзный Научно-Исследовательский Институт Молекулярной Биологии | Штамм гибридных культивируемых клеток животных MUS мUSсULUS L. - продуцент моноклональных антител к гликопротеиду Е1 вируса восточного энцефаломиелита лошадей |
| US5185440A (en) * | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| FR2659349B1 (fr) * | 1990-03-12 | 1993-12-24 | Rhone Merieux | Virus herpes recombinants notamment pour la realisation de vaccins, leur procede de preparation, les plasmides realises au cours de ce procede et les vaccins obtenus. |
| US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5243121A (en) | 1992-03-19 | 1993-09-07 | Engelhard Corporation | Fluid catalytic cracking process for increased formation of isobutylene and isoamylenes |
| US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
| EP1170368B1 (en) * | 1994-01-27 | 2010-07-28 | University Of Massachusetts Medical Center | Immunization by inoculation of dna transcription unit |
| FR2751226B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
| AU2948599A (en) * | 1998-03-27 | 1999-10-18 | Secretary Of State For Defence, The | Recombinant virus |
-
1996
- 1996-07-19 FR FR9609400A patent/FR2751226B1/fr not_active Expired - Lifetime
-
1997
- 1997-07-11 AR ARP970103113A patent/AR009947A1/es active IP Right Grant
- 1997-07-15 CZ CZ0017499A patent/CZ300593B6/cs not_active IP Right Cessation
- 1997-07-15 PL PL97331202A patent/PL188409B1/pl unknown
- 1997-07-15 EP EP97934569A patent/EP0936922B1/fr not_active Expired - Lifetime
- 1997-07-15 CA CA2260858A patent/CA2260858C/en not_active Expired - Lifetime
- 1997-07-15 WO PCT/FR1997/001314 patent/WO1998003198A1/fr not_active Ceased
- 1997-07-15 DE DE69734778T patent/DE69734778T2/de not_active Expired - Lifetime
- 1997-07-15 CA CA2660355A patent/CA2660355C/en not_active Expired - Lifetime
- 1997-07-15 NZ NZ333754A patent/NZ333754A/en not_active IP Right Cessation
- 1997-07-15 AU AU37727/97A patent/AU735372B2/en not_active Expired
- 1997-07-15 BR BR9710502A patent/BR9710502A/pt not_active Application Discontinuation
- 1997-07-15 EP EP05025200A patent/EP1647281A3/fr not_active Ceased
- 1997-07-15 JP JP09532943A patent/JP2000516199A/ja active Pending
- 1997-07-15 CZ CZ20080390A patent/CZ301365B6/cs not_active IP Right Cessation
-
1999
- 1999-01-15 US US09/232,478 patent/US6207166B1/en not_active Expired - Lifetime
-
2001
- 2001-02-16 US US09/785,055 patent/US6558674B1/en not_active Expired - Lifetime
-
2007
- 2007-03-12 AR ARP070101015A patent/AR059828A2/es unknown
- 2007-12-07 JP JP2007316669A patent/JP2008143900A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1647281A2 (fr) | 2006-04-19 |
| AR059828A2 (es) | 2008-04-30 |
| PL331202A1 (en) | 1999-07-05 |
| FR2751226B1 (fr) | 1998-11-27 |
| FR2751226A1 (fr) | 1998-01-23 |
| CZ301365B6 (cs) | 2010-01-27 |
| CA2660355A1 (en) | 1998-01-29 |
| NZ333754A (en) | 2001-03-30 |
| EP0936922B1 (fr) | 2005-11-30 |
| EP0936922A1 (fr) | 1999-08-25 |
| CA2660355C (en) | 2012-05-22 |
| JP2000516199A (ja) | 2000-12-05 |
| US6558674B1 (en) | 2003-05-06 |
| EP1647281A3 (fr) | 2009-08-05 |
| WO1998003198A1 (fr) | 1998-01-29 |
| CZ300593B6 (cs) | 2009-06-24 |
| DE69734778D1 (de) | 2006-01-05 |
| US6207166B1 (en) | 2001-03-27 |
| DE69734778T2 (de) | 2006-09-07 |
| AR009947A1 (es) | 2000-05-17 |
| BR9710502A (pt) | 1999-08-17 |
| PL188409B1 (pl) | 2005-01-31 |
| AU3772797A (en) | 1998-02-10 |
| CZ17499A3 (cs) | 1999-05-12 |
| AU735372B2 (en) | 2001-07-05 |
| CA2260858A1 (en) | 1998-01-29 |
| JP2008143900A (ja) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2260858C (en) | Polynucleotide vaccine formulation against pathologies of the horse | |
| US6586412B2 (en) | Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies | |
| US7534559B2 (en) | Feline polynucleotide vaccine formula | |
| US6376473B1 (en) | Polynucleotide vaccine formula in particular against bovine respiratory pathology | |
| US6576243B1 (en) | Polynucleotide vaccine formula against porcine reproductive and respiratory pathologies | |
| US7294338B2 (en) | Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies | |
| AU765539B2 (en) | Polynucleotide vaccine formula for treating horse diseases | |
| AU776827B2 (en) | Polynucleotide vaccine formula, particularly for treating bovine respiratory disease | |
| AU773266B2 (en) | Feline polynucleotide vaccine formula | |
| AU2004205140B2 (en) | Feline polynucleotide vaccine formula | |
| AU2004210602B2 (en) | Avian polynucleotide vaccine formula | |
| HK1083763A (zh) | 针对马科动物病变的多核苷酸疫苗配方 | |
| NZ506427A (en) | A canidae vaccine comprising the rabies G gene under the control of the CMV-IE promoter | |
| AU2007202367A1 (en) | Avian polynucleotide vaccine formula | |
| AU4614101A (en) | Avian polynucleotide vaccine formula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170717 |